Status:
RECRUITING
A Study to Evaluate the Efficacy and Safety of Dapagliflozin in Patient With Type 2 Diabetes Mellitus and Hypertension
Lead Sponsor:
Boryung Pharmaceutical Co., Ltd
Conditions:
Diabetes Mellitus
Hypertension
Eligibility:
All Genders
19+ years
Brief Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of dapagliflozin in patient with type 2 diabetes mellitus and hypertension
Eligibility Criteria
Inclusion
- Those diagnosed with type 2 diabetes mellitus accompanied by hypertension who are scheduled to be administrated Trudapa Tab. or Trudapa M SR Tab.
- Those who voluntarily signed a written personal information agreement to participate in this clinical study.
- Those able to understand this study, be cooperative in the execution of the study, and participate in the study until its completion.
Exclusion
- Patients with secondary hypertension: Secondary hypertension is not limited to the following diseases; (e.g., coarctation of the aorta, hyperaldosteronism, renal artery stenosis, pheochromocytoma, Cushing's syndrome and polycystic kidney disease, etc.)
- Those who have a history of taking dapagliflozin within 4 weeks of baseline (Visit 1)
- Those who are expected to need insulin prescription during the study period
- Pregnant women, breast-feeding women
Key Trial Info
Start Date :
July 26 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 21 2025
Estimated Enrollment :
9000 Patients enrolled
Trial Details
Trial ID
NCT05970237
Start Date
July 26 2023
End Date
October 21 2025
Last Update
September 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gachon University Gil Medical Center
Incheon, Namdong-gu, South Korea, 21565